Shortage update · Resolved
Wegovy supply normalization (shortage status removed Q4 2025)
Wegovy · Announced 2025-11-10 · Last reviewed May 2026
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of May 2026; updated when guidance or availability changes.
Following more than two years of intermittent Wegovy supply constraints, Novo Nordisk announced in November 2025 that all dose strengths of Wegovy are now available in sufficient supply to meet demand. The FDA subsequently removed all Wegovy dose strengths from the FDA Drug Shortage list. This normalization has narrowed the legal basis for compounding semaglutide — 503A compounding pharmacies historically relied on the FDA shortage list to justify compounded semaglutide production. As of 2026, telehealth services that previously offered compounded semaglutide have been transitioning patients to branded Wegovy or to alternative therapies.
What's affected
- All Wegovy dose strengths (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg)
- Indirectly: compounded semaglutide products from 503A pharmacies
What patients should do
- If currently on compounded semaglutide, ask your prescriber about transitioning to branded Wegovy
- If using Novo's NovoCare self-pay program, eligibility remains at ~$499/month
- If your prior auth was previously denied due to shortage workarounds, ask your prescriber to resubmit now that branded supply is normalized